Therabron Therapeutics, a US-based biotechnology company focused on respiratory diseases, secured a $6.75m extension for its series B round yesterday led by Brace Pharma Capital, the local investment unit of pharmaceutical firm EMS.
Brace Pharma already contributed funds to the round’s first tranche of $11m in December 2014. That first part was also backed by Zell Biotech Two and three unnamed investors.
Founded in 2007, Therabron is developing treatments for acute and chronic respiratory diseases. The company’s drug candidates are aimed at restoring the natural immune balance in patients’ lungs.
The series B extension will fund continued development of Therabron’s lead drug candidate, which is currently undergoing a phase 2 clinical trial, and the company’s platform.
Therabron has not disclosed details about its series A round.